Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a PK and dose-response study of asfotase alfa in adults with pediatric-onset hypophosphatasia
2015-003131-35Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of asfotase alfa in hypophosphatasia (HPP) (3 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change in plasma inorganic pyrophosphate (PPi). Started Dec 2015; status: completed.
02
Drugs
asfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on 2015-003131-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003131-35.